title: Regenerative Medicines for Remyelination: From Aspiration to Reality.
abstract: Stimulating an endogenous regenerative response is a powerful approach for potential treatment of chronic demyelinating diseases such as multiple sclerosis. Recently in Nature, Najm et al. (2015) identified two clinically relevant, FDA-approved compounds that promote oligodendrocyte progenitor cell differentiation and induce remyelination in demyelinating disease models.
authors.affiliation: Wellcome Trust-MRC Cambridge Stem Cell Institute, The Clifford Allbutt Building, Cambridge Biomedical Campus, University of Cambridge, Hills Road, Cambridge CB2 0AH, UK. Electronic address: rjf1000@cam.ac.uk.
authors.forename: Robin J M
authors.initials: RJ
authors.lastname: Franklin
mesh_terms: D000818:Animals; D002990:Clobetasol / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008825:Miconazole / Q000494:pharmacology*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000378:metabolism*; D009186:Myelin Sheath / Q000187:drug effects* / Q000378:metabolism*; D039904:Pluripotent Stem Cells / Q000187:drug effects*
chemical_list: D008825:Miconazole; D002990:Clobetasol